Gastrointestinal stromal tumors

Report of an audit and review of the literature

Guido Biasco, Daniela Velo, Imerio Angriman, Maria Astorino, Anna Baldan, Matteo Baseggio, Umberto Basso, Giorgio Battaglia, Matteo Bertin, Roberta Bertorelle, Paolo Bocus, Piero Brosolo, Andrea Bulzacchi, Renato Cannizzaro, Gian Franco Da Dalt, Monica Di Battista, Domenico Errante, Marny Fedrigo, Sergio Frustaci, Ivana Lionetti & 15 others Marco Massani, Roberto Mencarelli, Maria Cristina Montesco, Lorenzo Norberto, Maria Abbondanza Pantaleo, Claudio Pasquali, Davide Pastorelli, Carlo Remigio Rossi, Cesare Ruffolo, Luigi Salvagno, Maria Stella Saponara, Fabrizio Vittadello, Francesco Zaccaria, Stefania Zovato, Fabio Farinati

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors (GISTs), tumors characterized by c-KIT mutations, are the most frequent mesenchymal tumors of the digestive tract. The stomach is the most commonly involved site. Localization, size and mitotic rate are reliable predictors of survival and the two milestones of GISTs treatment are surgery and imatinib. This article is aimed to report the data of an audit, carried out on the morphological and clinical aspects of the disease and to review the present knowledge on GISTs. A total of 172 patients with GISTs (M:F= 1:1; mean age 65 years) were recruited. The stomach was the most frequently involved site. In 50% of the cases the tumor was smaller than 5cm, whereas major symptoms were observed in 43% of the cases. Predictors of progressive disease were present only in a small percentage of cases but the disease was in the metastatic phase in over 25% of the cases at diagnosis. Familial aggregation was rare but a consistent share of the patients (21%) had other synchronous or metachronous cancers. The most frequent mutations were in-frame deletions and point mutations of c-KIT exon 11. This report confirms in part the available data on GIST in a consecutive series of patients recruited in Italy and shows that only large collaborative multicenter studies provide data sound enough to enable making reasonable clinical and therapeutic choices, and suggests that, as a measure of secondary prevention, a diagnostic definition should be obtained in all submucosal lesions of the GI tract and that GIST patients should be screened for second tumors.

Original languageEnglish
Pages (from-to)106-116
Number of pages11
JournalEuropean Journal of Cancer Prevention
Volume18
Issue number2
DOIs
Publication statusPublished - Apr 2009

Fingerprint

Gastrointestinal Stromal Tumors
Neoplasms
Gastrointestinal Tract
Stomach
Mutation
Sequence Deletion
Secondary Prevention
Point Mutation
Italy
Multicenter Studies
Exons
Survival
Therapeutics

Keywords

  • Audit gastrointestinal stromal tumors
  • Oncology

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Epidemiology
  • Public Health, Environmental and Occupational Health

Cite this

Biasco, G., Velo, D., Angriman, I., Astorino, M., Baldan, A., Baseggio, M., ... Farinati, F. (2009). Gastrointestinal stromal tumors: Report of an audit and review of the literature. European Journal of Cancer Prevention, 18(2), 106-116. https://doi.org/10.1097/CEJ.0b013e32830c8da8

Gastrointestinal stromal tumors : Report of an audit and review of the literature. / Biasco, Guido; Velo, Daniela; Angriman, Imerio; Astorino, Maria; Baldan, Anna; Baseggio, Matteo; Basso, Umberto; Battaglia, Giorgio; Bertin, Matteo; Bertorelle, Roberta; Bocus, Paolo; Brosolo, Piero; Bulzacchi, Andrea; Cannizzaro, Renato; Da Dalt, Gian Franco; Di Battista, Monica; Errante, Domenico; Fedrigo, Marny; Frustaci, Sergio; Lionetti, Ivana; Massani, Marco; Mencarelli, Roberto; Montesco, Maria Cristina; Norberto, Lorenzo; Pantaleo, Maria Abbondanza; Pasquali, Claudio; Pastorelli, Davide; Rossi, Carlo Remigio; Ruffolo, Cesare; Salvagno, Luigi; Saponara, Maria Stella; Vittadello, Fabrizio; Zaccaria, Francesco; Zovato, Stefania; Farinati, Fabio.

In: European Journal of Cancer Prevention, Vol. 18, No. 2, 04.2009, p. 106-116.

Research output: Contribution to journalArticle

Biasco, G, Velo, D, Angriman, I, Astorino, M, Baldan, A, Baseggio, M, Basso, U, Battaglia, G, Bertin, M, Bertorelle, R, Bocus, P, Brosolo, P, Bulzacchi, A, Cannizzaro, R, Da Dalt, GF, Di Battista, M, Errante, D, Fedrigo, M, Frustaci, S, Lionetti, I, Massani, M, Mencarelli, R, Montesco, MC, Norberto, L, Pantaleo, MA, Pasquali, C, Pastorelli, D, Rossi, CR, Ruffolo, C, Salvagno, L, Saponara, MS, Vittadello, F, Zaccaria, F, Zovato, S & Farinati, F 2009, 'Gastrointestinal stromal tumors: Report of an audit and review of the literature', European Journal of Cancer Prevention, vol. 18, no. 2, pp. 106-116. https://doi.org/10.1097/CEJ.0b013e32830c8da8
Biasco, Guido ; Velo, Daniela ; Angriman, Imerio ; Astorino, Maria ; Baldan, Anna ; Baseggio, Matteo ; Basso, Umberto ; Battaglia, Giorgio ; Bertin, Matteo ; Bertorelle, Roberta ; Bocus, Paolo ; Brosolo, Piero ; Bulzacchi, Andrea ; Cannizzaro, Renato ; Da Dalt, Gian Franco ; Di Battista, Monica ; Errante, Domenico ; Fedrigo, Marny ; Frustaci, Sergio ; Lionetti, Ivana ; Massani, Marco ; Mencarelli, Roberto ; Montesco, Maria Cristina ; Norberto, Lorenzo ; Pantaleo, Maria Abbondanza ; Pasquali, Claudio ; Pastorelli, Davide ; Rossi, Carlo Remigio ; Ruffolo, Cesare ; Salvagno, Luigi ; Saponara, Maria Stella ; Vittadello, Fabrizio ; Zaccaria, Francesco ; Zovato, Stefania ; Farinati, Fabio. / Gastrointestinal stromal tumors : Report of an audit and review of the literature. In: European Journal of Cancer Prevention. 2009 ; Vol. 18, No. 2. pp. 106-116.
@article{41ec2fc6f6a34635b379e77f6c80d667,
title = "Gastrointestinal stromal tumors: Report of an audit and review of the literature",
abstract = "Gastrointestinal stromal tumors (GISTs), tumors characterized by c-KIT mutations, are the most frequent mesenchymal tumors of the digestive tract. The stomach is the most commonly involved site. Localization, size and mitotic rate are reliable predictors of survival and the two milestones of GISTs treatment are surgery and imatinib. This article is aimed to report the data of an audit, carried out on the morphological and clinical aspects of the disease and to review the present knowledge on GISTs. A total of 172 patients with GISTs (M:F= 1:1; mean age 65 years) were recruited. The stomach was the most frequently involved site. In 50{\%} of the cases the tumor was smaller than 5cm, whereas major symptoms were observed in 43{\%} of the cases. Predictors of progressive disease were present only in a small percentage of cases but the disease was in the metastatic phase in over 25{\%} of the cases at diagnosis. Familial aggregation was rare but a consistent share of the patients (21{\%}) had other synchronous or metachronous cancers. The most frequent mutations were in-frame deletions and point mutations of c-KIT exon 11. This report confirms in part the available data on GIST in a consecutive series of patients recruited in Italy and shows that only large collaborative multicenter studies provide data sound enough to enable making reasonable clinical and therapeutic choices, and suggests that, as a measure of secondary prevention, a diagnostic definition should be obtained in all submucosal lesions of the GI tract and that GIST patients should be screened for second tumors.",
keywords = "Audit gastrointestinal stromal tumors, Oncology",
author = "Guido Biasco and Daniela Velo and Imerio Angriman and Maria Astorino and Anna Baldan and Matteo Baseggio and Umberto Basso and Giorgio Battaglia and Matteo Bertin and Roberta Bertorelle and Paolo Bocus and Piero Brosolo and Andrea Bulzacchi and Renato Cannizzaro and {Da Dalt}, {Gian Franco} and {Di Battista}, Monica and Domenico Errante and Marny Fedrigo and Sergio Frustaci and Ivana Lionetti and Marco Massani and Roberto Mencarelli and Montesco, {Maria Cristina} and Lorenzo Norberto and Pantaleo, {Maria Abbondanza} and Claudio Pasquali and Davide Pastorelli and Rossi, {Carlo Remigio} and Cesare Ruffolo and Luigi Salvagno and Saponara, {Maria Stella} and Fabrizio Vittadello and Francesco Zaccaria and Stefania Zovato and Fabio Farinati",
year = "2009",
month = "4",
doi = "10.1097/CEJ.0b013e32830c8da8",
language = "English",
volume = "18",
pages = "106--116",
journal = "European Journal of Cancer Prevention",
issn = "0959-8278",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Gastrointestinal stromal tumors

T2 - Report of an audit and review of the literature

AU - Biasco, Guido

AU - Velo, Daniela

AU - Angriman, Imerio

AU - Astorino, Maria

AU - Baldan, Anna

AU - Baseggio, Matteo

AU - Basso, Umberto

AU - Battaglia, Giorgio

AU - Bertin, Matteo

AU - Bertorelle, Roberta

AU - Bocus, Paolo

AU - Brosolo, Piero

AU - Bulzacchi, Andrea

AU - Cannizzaro, Renato

AU - Da Dalt, Gian Franco

AU - Di Battista, Monica

AU - Errante, Domenico

AU - Fedrigo, Marny

AU - Frustaci, Sergio

AU - Lionetti, Ivana

AU - Massani, Marco

AU - Mencarelli, Roberto

AU - Montesco, Maria Cristina

AU - Norberto, Lorenzo

AU - Pantaleo, Maria Abbondanza

AU - Pasquali, Claudio

AU - Pastorelli, Davide

AU - Rossi, Carlo Remigio

AU - Ruffolo, Cesare

AU - Salvagno, Luigi

AU - Saponara, Maria Stella

AU - Vittadello, Fabrizio

AU - Zaccaria, Francesco

AU - Zovato, Stefania

AU - Farinati, Fabio

PY - 2009/4

Y1 - 2009/4

N2 - Gastrointestinal stromal tumors (GISTs), tumors characterized by c-KIT mutations, are the most frequent mesenchymal tumors of the digestive tract. The stomach is the most commonly involved site. Localization, size and mitotic rate are reliable predictors of survival and the two milestones of GISTs treatment are surgery and imatinib. This article is aimed to report the data of an audit, carried out on the morphological and clinical aspects of the disease and to review the present knowledge on GISTs. A total of 172 patients with GISTs (M:F= 1:1; mean age 65 years) were recruited. The stomach was the most frequently involved site. In 50% of the cases the tumor was smaller than 5cm, whereas major symptoms were observed in 43% of the cases. Predictors of progressive disease were present only in a small percentage of cases but the disease was in the metastatic phase in over 25% of the cases at diagnosis. Familial aggregation was rare but a consistent share of the patients (21%) had other synchronous or metachronous cancers. The most frequent mutations were in-frame deletions and point mutations of c-KIT exon 11. This report confirms in part the available data on GIST in a consecutive series of patients recruited in Italy and shows that only large collaborative multicenter studies provide data sound enough to enable making reasonable clinical and therapeutic choices, and suggests that, as a measure of secondary prevention, a diagnostic definition should be obtained in all submucosal lesions of the GI tract and that GIST patients should be screened for second tumors.

AB - Gastrointestinal stromal tumors (GISTs), tumors characterized by c-KIT mutations, are the most frequent mesenchymal tumors of the digestive tract. The stomach is the most commonly involved site. Localization, size and mitotic rate are reliable predictors of survival and the two milestones of GISTs treatment are surgery and imatinib. This article is aimed to report the data of an audit, carried out on the morphological and clinical aspects of the disease and to review the present knowledge on GISTs. A total of 172 patients with GISTs (M:F= 1:1; mean age 65 years) were recruited. The stomach was the most frequently involved site. In 50% of the cases the tumor was smaller than 5cm, whereas major symptoms were observed in 43% of the cases. Predictors of progressive disease were present only in a small percentage of cases but the disease was in the metastatic phase in over 25% of the cases at diagnosis. Familial aggregation was rare but a consistent share of the patients (21%) had other synchronous or metachronous cancers. The most frequent mutations were in-frame deletions and point mutations of c-KIT exon 11. This report confirms in part the available data on GIST in a consecutive series of patients recruited in Italy and shows that only large collaborative multicenter studies provide data sound enough to enable making reasonable clinical and therapeutic choices, and suggests that, as a measure of secondary prevention, a diagnostic definition should be obtained in all submucosal lesions of the GI tract and that GIST patients should be screened for second tumors.

KW - Audit gastrointestinal stromal tumors

KW - Oncology

UR - http://www.scopus.com/inward/record.url?scp=61449255585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449255585&partnerID=8YFLogxK

U2 - 10.1097/CEJ.0b013e32830c8da8

DO - 10.1097/CEJ.0b013e32830c8da8

M3 - Article

VL - 18

SP - 106

EP - 116

JO - European Journal of Cancer Prevention

JF - European Journal of Cancer Prevention

SN - 0959-8278

IS - 2

ER -